Overton Brooks VA Medical Center, Shreveport, LA
Is Overton Brooks VA Medical Center registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Overton Brooks VA Medical Center hold a Louisiana pharmacy license?
State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search.
Has Overton Brooks VA Medical Center had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jun 11, 2025) for Overton Brooks VA Medical Center. State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Overton Brooks VA Medical Center
- Location
- Shreveport, LA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 11, 2025
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 16 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Overton Brooks VA Medical Center, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jun 11, 2025 | FMD-145 letter | FMD-145 Letter Issued 06/11/2025 | Not linked by FDA |
| Dec 18, 2024 | Form 483 | 483 Issued 12/18/2024 | FDA copy (archived) |
| Feb 12, 2020 | Form 483 | 483 Issued 02/12/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Overton Brooks VA Medical Center, Shreveport, LA (FEI number 3013236711), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Dec 18, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013236711 | 1257010 |
| Feb 17, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013236711 | 1002344 |
Form 483s FDA has published for this site
- Dec 18, 2024: Form 483 to Overton Brooks VA Medical Center, published Feb 7, 2025. fda.gov
- Feb 12, 2020: Form 483 to Overton Brooks VA Medical Center, published Nov 20, 2020. fda.gov
- Apr 12, 2017: Form 483 to Overton Brooks VA Medical Center, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 3 inspections ending Apr 12, 2017 to Dec 18, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Dec 10, 2024 to Dec 18, 2024: 3 observations
- Firm on the cover
- Overton Brooks VA Medical Center, 510 E Stoner Ave, Shreveport, LA 71101-4243
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Products
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically,
During production of Fluorouracil 50mg/ml in your firm's hazardous clean room on 12/11/2024, your firm's pharmacist inadvertently threw away the drug product from the ISO-5 hood prior to adding the total amount needed to the finished product. Your pharmacist retrieved the drug product from the hazardous waste bin located under the ISO-5 hood, wiped the vial with sterile <Redacted B4> then proceeded to use the product to finish producing. This hazardous waste bin was approximately 314th full of various hazardous products when the pharmacist retrieved the Fluorouracil. Your pharmacist was on their way to put the finished product in the pass through for use when I stopped them to ask what they planned to do with the product. Your pharmacist then decided to remake the product.
In addition, your pharmacist did not perform decontamination and deactivation cleaning steps in the ISO-5 work area after introducing product from the hazardous waste bin. ...
Observation 2
Personnel infrequently changed and sanitized gloves to prevent contamination.
Specifically,
During production on 12/11/2024, I observed the following instances of infrequent glove changes/sanitation:
D During production of leucovorin 10mg/ml in the chemo buffer room, I observed your pharmacist remove vials and packaging components from the ISO-5 workspace to make room to work. After disposing of the vials and components in the trash bin and hazardous bin, the pharmacist returned to production in the ISO-5 hood without sanitizing their gloved hands. This leucovorin product was administered to a veteran.
D During production of leucovorin 10mg/ml in the chemo buffer room, I observed your pharmacist remove their hands from the ISO-5 environment to verify a label outside of the ISO-5 environment. The pharmacist returned to the ISO-5 hood without sanitizing their hands. This leucovorin product was administered to a veteran.
□ During production of enfortumab vedotin-ejfv l0mg/ml in the chemo buffer room, I observed your pharmacist remove their hands from the ISO-5 hood, adjust their face mask, then return to production activities. ...
Observation 3
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
Media fills are performed filling <Redacted B4> media into vials. Your firm does not produce any products in vials. The most common final packaging is IV Bag followed by syringe. Your firm's current media fill protocol requires operators to perform <Redacted B4> sets of <Redacted B4> transfers into a final vial container. During production of on 12/11/24, I observed up to ten or more transfers. <Redacted B4> vials were reconstituted and then each vial's contents were filled into an IV bag during production of enfortumab vedotin-ejfv l0mg/ml in the chemo buffer room.
Inspection dated Feb 12, 2020 by FDA (dates on the form not read): 3 observations
- Firm on the cover
- Overton Brooks VA Medical Center, 510 E Stoner Ave, Shreveport, LA 71101 -4243
- FEI number
- 3013236711
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- U.S. Food and Drug Administration 404 BNA Drive, Bldg 200, Suite 500 Nashville, TN 37217
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
he ISO 5 classified aseptic processing area was located within a non-classified room (segregated production area).
Specifically, your firm's ISO-5 classified <Redacted B4> located in the Hazardous Area Room <Redacted B4> and the ISO-5 classified <Redacted B4> located in the Non-Hazardous Area (Room <Redacted B4> are in unclassified rooms. These <Redacted B4> contain a <Redacted B4> antechamber. The <Redacted B4> chamber is under <Redacted B4> pressure. According to your firm's Inpatient Pharmacy Manager, the antechambers do not supply a continuous flow of HEPA filtered air.
On 3 February 2020, we observed your pharmacist open the <Redacted B4> ISO-5 classified antechamber exposing the inside of the antechamber to the unclassified air in the surrounding room, during the transfer of materials from the "segregated compounding area" (SCA) into the antechamber. In addition, prior to the movement of these materials, the antechamber's interior surfaces were not disinfected.
Your firm performs aseptic operations within the <Redacted B4> and <Redacted B4> to produce sterile hazardous and nonhazardous drug products. ...
Observation 2
Equipment in close enough proximity to the ISO 5 area that could compromise the air in the ISO 5 area.
Specifically, on 3 February 2020, we observed a portable air conditioner in your firm's non-hazardous segregated compounding area" (SCA) (Rm <Redacted B4> which contains a condenser water tank. According to your Chief of Pharmacy, the portable air conditioner is located approximately 97 inches from your firm's <Redacted B4> (ISO-5 Classified), where aseptic operations are performed for non-hazardous sterile drug products. According to your firm's Inpatient Pharmacy Manager, the antechambers do not supply a continuous flow of HEPA filtered air.
According to your firm's Chief of Pharmacy, the portable air conditioner has been in your firm's non-hazardous SCA from June 2017-: 4 February 2020. Per your firm's <Redacted B4> prescription log, your firm has approximately produced <Redacted B4> sterile drug products in the <Redacted B4>
Observation 3
The facility design of your segregated production area does not have a suitable construction to facilitate cleaning, maintenance, and proper operations.
Specific.ally
A. Your firm's Hazardous Area (Room <Redacted B4>, containing the ISO-5 Classified <Redacted B4> where aseptic operations are performed, was observed to have:
a. A wooden door that separates Room <Redacted B4> from a corridor that is readily accessible to the public. This corridor is located near an exterior entrance door. This room is under <Redacted B4> pressure.
b. A refrigerator with a fan unit which intakes and exhausts air through two vents located above the refrigerator door. The refrigerator is located approximately 30 inches from the <Redacted B4>
B. Your firm's Non-Hazardous Area (Room <Redacted B4>, containing the ISO-5 Classified <Redacted B4> where aseptic operations are performed, was observed to have:
a. A wooden door that separates Room <Redacted B4> from a common hallway accessible to the public.
b. Flooring that is not smooth and even (e.g. crevices and gaps were observed). ...
Inspection dated Apr 12, 2017 by FDA (dates on the form not read): 10 observations
- Firm on the cover
- Overton Brooks VA Medical Center, 510 E Stoner Ave, Shreveport, LA 71101- 4243
- FEI number
- 3013236711
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- New Orleans District Office 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The system for cleaning and disinfecting the aseptic processing areas are deficient.
Specifically,
1. <Redacted B4> cleaning within the pharmacy cleanrooms were done sporadically.
a. The Environmental Management Service (EMS) department is responsible for conducting <Redacted B4> cleanings <Redacted B4> cleanings) and (15J<4 cleanings (mopping floors an d cleaning door handles). For example, 2016 pharmacy cleaning records document:
i. N o <Re dacted B4> cleanings occurred <Redacted B4>. ii. N o <Redacted B4> cleanings occurred <Redacted B4>.
J
b . Pharmacy staff is responsible for conducting <Redacted B4> cleanings of the <Redacted B4> Laminar Air Flow Workspace LAFW (ISO 5 Hood) and <Redacted B4> (ISO 5). For example, 2016 pharmacy cleaning records document:
I
D 4 1. <Redacted B4> cleanings did not occur <Redacted B4> for the <Redacted B4> (ISO 5) .
11. <Redacted B4> cleanings did not occur <Redacted B4> for the LAFW (ISO 5 Hood).
2 . Housekeeping personnel stated they have entered into the ISO 7 areas to mop and empty the trash while a pharmacist or pharmacy technician is actively performing aseptic operations.
3. Visible discoloration that appears to be rust was observed:
a. ...
Observation 2
1Y our firm continued producing sterile drug products while construction was ongoing within your facility without establishing adequate controls to prevent contamination of the production environment.
Specifically, your firm produced sterile drugs on 06/10/2010 and did not have adequate controls in place to protect the production environment within these areas. The initial air certification for the clean rooms 11ISO 7 and ISO 8 areas), LAFW (ISO 5 Hood) and <Redacted B4> (ISO 5) were completed on[{6) {<4) J. !However, the occupancy release date for the clean rooms was <Redacted B4>. Furthermore, additional construction occurred in the general pharmacy area during this time and was not completed until 2/01/2011. Your firm continued to produce sterile drug product in the Chemo Buffer Room and IV !Buffer Room.
Observation 3
Th e system for monitoring and maintaining environmental conditions in the aseptic processing areas was deficient.
Specifically, the air and surface samples lack meaningful data. For example,
I
1. Your firm used <Redacted B4> to conduct in-house surface sampling, air sampling, and personnel fingertip sampling. According to the manufacturer's recommendations, this media requires incubation in a controlled environment. Your firm failed to place the <Redacted B4> in an appropriate controlled environment.
2 . In 2016, surface and air sampling was not performed in the <Redacted B4> (ISO 5).
3. In 2016, your firm failed to conduct fingertip sampling on approximately 27% of your pharmacist and approximately 43% of your pharmacy technicians.
a. In addition, recorded growth for Staph, was documented on 09/13/2012 for who performs aseptic operations. According to your firm, <Redacted B4> continued to perform aseptic operations.
l::l· .,
b . On 02/01/2017, your firm used an outside contractor to conduct viable surface and nonviable air samples . However, the contractor's sampling plan did not represent worst-case activities and conditions that provide a challenge to aseptic operations. ...
Observation 4
Personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with glovedhands and then proceeding with aseptic processing without changing or sanitizing gloves .
Specifically,
Observation 5
Personnel were observed conducting aseptic manipulations or placing equipment/supplies in an area that blocked the movement of first pass air around an open unit, whether before or after it is filled with sterile product.
Specifically, during aseptic operations, a pharmacy technician was observed placing their hands in the path unidirectional airflow under the LAFW (ISO 5) over open units with sterile product, therefore blocking he movement of first pass air. Additionally, on 02/06/2017, your pharmacy technician was observed to be moving rapidly in the vicinity of open sterile vicinity, which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 area.
Observation 6
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Observation 7
Equipment, materials, and/or supplies are not disinfected prior to entering the aseptic processing areas.
Observation 8
Your firm did not conduct smoke studies of the aseptic processing area under dynamic conditions.
Specifically, during the <Redacted B4> certification, unidirectional airflow was not verified under operational conditions under the <Redacted B4> (ISO 5).
L...
Observation 9
There is inadequate HEPA filter coverage or airflow over the area to which sterile product is exposed.
Specifically,
1. Your firm failed, 4 consecutive re-certifications ( on <Redacted B4> respectively) for the HEPA filters located in the Air Handling Unit (AHU). The AHU supples clean air into all the clean rooms. This air does not pass through additional HEPA filters before entering the IV Buffer Room (ISO 7) and Chemo Buffer Room (ISO 7). In addition, your firm did not conduct the scheduled re-certification test for <Redacted B4>. Your firm did not provide any documentation supporting these failures were corrected.
2 . A leak was detected on <Redacted B4> during the re-certification of your LAFW (ISO 5 Hood), located in the IV Buffer Room. Your firm did not provide any documentation supporting this leak was conected.
3. Your firm failed to re-certify the clean rooms after maintenance and repairs were conducted on the HEPA filters in the AHU on 01/14/2016, 10/31-11/01/2016, and 02/02-03/2017 . However, your firm continued to perform aseptic operations.
4 . ...
Observation 10
Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.
Specifically,
I
1. The gasket that <Redacted B4> located on the ceiling directly above the <Redacted B4> (ISO 5) located in the Chemo Buffer Room and directly above the LAFW (ISO 5 Hood) located in the IV Buffer Room is frayed.
2 . Multiple ledges are present in the IV Buffer Room and Chemo Buffer Room (i.e. base boards <Redacted B4>)
a. What appears to be sheet rock dust was observed on the baseboard located approximately 2 feet from the LAFW (ISO 5 Hood) in the IV Buffer room. 3. A crack, approximately 4 inches long, which created a gap, was observed on the florescent light cover located on ceiling of LAFW (ISO 5 Hood).
4. A missing bolt was observed underneath the return air slot, creating approximately a 2 mm gap.
State board of pharmacy records
State board of pharmacy records for Louisiana are not checked: no license file or list of board actions was found on the board’s website when checked on November 10, 2026; its credential verification is an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.